Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation
Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...
914 Views
Opportunities in The (Overpriced) Japan Pharma Sector
As a defensive sector, Japan’s pharmaceutical sector has had an up-and-down time of it during the Abe era. In the early days of Abenomics, the...
237 Views
Key ESG Engagement Questions - Healthcare Sector
Directly engaging with companies is often the solution to better understand risks, cultures and operational performance. In instances of ESG...
774 Views
Biosimilar Battlefield: An Update
Korea's biosimilar plays, Celltrion Inc (068270 KS) , Celltrion Pharm Inc (068760 KS) , Celltrion Healthcare (091990 KS) , and Samsung Biologics...
518 Views
Sanofi: Stop the Bleeding with Bioverativ
Today, Sanofi (SAN FP) announced that it is acquiring Bioverativ Inc (BIVV US) for $11.6 billion (a 64% premium). Management hosted a conference...
376 Views